Vanert M, Battigelli M C
Ann Allergy. 1975 Sep;35(3):142-7.
The pharmacological action of TDI (toluene-diisocyanate) has been measured in vitro, using peripheral leukocytes of human blood. In this system TDI does not release histamine but it appears to contribute to the action of histamine and other mediators by moderating the beta-adrenergic function. Like propranolol TDI reduces the CAMP (cyclic AMP) stimulation produced by cathecolamines. However it differs from propranolol through its inhibition of the glucagon effect on CAMP (which propranolol does not possess) and also by inhibiting antigenic release of histamine.
已利用人体外周血白细胞在体外测定了甲苯二异氰酸酯（TDI）的药理作用。在该系统中，TDI不会释放组胺，但它似乎通过调节β-肾上腺素能功能来促进组胺和其他介质的作用。与普萘洛尔一样，TDI会降低儿茶酚胺产生的环磷酸腺苷（CAMP）刺激。然而，它与普萘洛尔的不同之处在于，它抑制胰高血糖素对CAMP的作用（普萘洛尔没有这种作用），并且还抑制组胺的抗原性释放。
